Coya Therapeutics (NASDAQ:COYA) Receives "Buy" Rating from D. Boral Capital

Coya Therapeutics (NASDAQ:COYA - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at D. Boral Capital in a research report issued on Thursday,Benzinga reports. They presently have a $18.00 price target on the stock. D. Boral Capital's target price points to a potential upside of 171.90% from the stock's previous close.

A number of other research analysts also recently issued reports on COYA. Wall Street Zen downgraded shares of Coya Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. HC Wainwright restated a "buy" rating and issued a $18.00 price target on shares of Coya Therapeutics in a research report on Monday, June 9th. Lake Street Capital started coverage on shares of Coya Therapeutics in a research report on Wednesday, July 9th. They issued a "buy" rating and a $16.00 price target on the stock. Finally, Chardan Capital restated a "buy" rating and issued a $14.00 price target on shares of Coya Therapeutics in a research report on Tuesday, July 1st. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $16.50.

Coya Therapeutics Trading Down 0.7%

NASDAQ:COYA traded down $0.05 during mid-day trading on Thursday, hitting $6.62. 83,862 shares of the company's stock were exchanged, compared to its average volume of 76,897. The company has a 50 day simple moving average of $5.83 and a 200-day simple moving average of $6.04. Coya Therapeutics has a fifty-two week low of $4.65 and a fifty-two week high of $10.24. The firm has a market capitalization of $110.75 million, a P/E ratio of -6.19 and a beta of 0.26.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.44) EPS for the quarter, hitting the consensus estimate of ($0.44). The business had revenue of $257.88 million for the quarter, compared to analyst estimates of $2.63 million. As a group, analysts expect that Coya Therapeutics will post -1.15 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC increased its stake in Coya Therapeutics by 1,005.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company's stock valued at $30,000 after purchasing an additional 4,777 shares in the last quarter. Charles Schwab Investment Management Inc. bought a new stake in shares of Coya Therapeutics in the 1st quarter worth $65,000. XTX Topco Ltd bought a new stake in shares of Coya Therapeutics in the 4th quarter worth $59,000. Jane Street Group LLC bought a new stake in shares of Coya Therapeutics in the 4th quarter worth $74,000. Finally, Northern Trust Corp boosted its holdings in shares of Coya Therapeutics by 12.2% in the 4th quarter. Northern Trust Corp now owns 28,549 shares of the company's stock worth $164,000 after buying an additional 3,099 shares during the last quarter. Institutional investors and hedge funds own 39.75% of the company's stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.